大麻素1型受体调控肾脏GLUT2:糖尿病肾病治疗新启示
糖尿病时GLUT2介导的葡萄糖重吸收改变可致肾近端小管细胞损伤、炎症和间质纤维化,CB1R激活也参与糖尿病肾病发生。该小鼠研究显示,外周CB1R阻断或RPTCs中CB1R基因失活可改善糖尿病引起的肾脏结构和功能改变、炎症及小管间质纤维化。抑制CB1R还下调GLUT2表达、影响其向刷状缘膜动态转位并减少葡萄糖重吸收。
要点
- 外周CB1R阻断或RPTCs中CB1R失活可改善糖尿病小鼠肾脏结构功能、炎症和纤维化
- 抑制CB1R下调GLUT2表达,影响其向刷状缘膜转位并减少葡萄糖重吸收
- 靶向外周CB1R或RPTCs中GLUT2动态可能治疗和改善糖尿病肾病
核心结论
- 靶向外周CB1R或抑制RPTCs中GLUT2动态有潜力治疗和改善糖尿病肾病。
- 研究结果可能支持外周限制性CB1R拮抗剂的临床测试或开发新型肾脏特异性GLUT2抑制剂对抗糖尿病肾病。
研究设计与样本
- 小鼠研究,采用慢性外周CB1R阻断或RPTCs中CB1R基因失活。
主要发现
- 慢性外周CB1R阻断或RPTCs中CB1R基因失活可改善糖尿病诱导的肾脏结构和功能改变、肾脏炎症及小管间质纤维化。
- 抑制CB1R下调GLUT2表达,影响GLUT2向RPTCs刷状缘膜的动态转位,并减少葡萄糖重吸收。
临床怎么用
- 研究提示外周限制性CB1R拮抗剂或肾脏特异性GLUT2抑制剂可能成为糖尿病肾病治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Altered glucose reabsorption via the facilitative glucose transporter 2 (GLUT2) during diabetes may lead to renal proximal tubule cell (RPTC) injury, inflammation, and interstitial fibrosis. These pathologies are also triggered by activating the cannabinoid-1 receptor (CB1R), which contributes to the development of diabetic nephropathy (DN). However, the link between CB1R and GLUT2 remains to be determined. Here, we show that chronic peripheral CB1R blockade or genetically inactivating CB1Rs in the RPTCs ameliorated diabetes-induced renal structural and functional changes, kidney inflammation, and tubulointerstitial fibrosis in mice. Inhibition of CB1R also downregulated GLUT2 expression, affected the dynamic translocation of GLUT2 to the brush border membrane of RPTCs, and reduced glucose reabsorption. Thus, targeting peripheral CB1R or inhibiting GLUT2 dynamics in RPTCs has the potential to treat and ameliorate DN. These findings may support the rationale for the clinical testing of peripherally restricted CB1R antagonists or the development of novel renal-specific GLUT2 inhibitors against DN.
引用
- Hinden L, Udi S, Drori A, et al. Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy. J Am Soc Nephrol. 2017. PMID: 29030466. doi:10.1681/ASN.2017040371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。